Longevity & Aging · Metabolic & Cardiometabolic
testosterone and TRT does not cause prostate cancer
In plain terms: Is prostate cancer risk unchanged by testosterone level (the saturation model)?
The old "testosterone feeds prostate cancer" fear is not supported by modern data — androgen receptors saturate at low T, and TRT has not been shown to raise prostate-cancer risk in reassuring but non-randomized evidence.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
The old fear that testosterone feeds prostate cancer is not supported by modern data: a meta-analysis of 41 randomised trials in 11,161 men found no significant increase in prostate cancer, TRAVERSE found no excess events, and in the REDUCE placebo arm neither testosterone nor DHT predicted risk. Most supporting evidence is non-randomised and reassuring rather than definitive.
The evidence (13)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Ory J, Flannigan R, Lundeen C, Huang JG, Pommerville P, Goldenberg SL 2016 · J Urol | observational | supports | moderate | Independent cohort: TRT in men with treated/untreated prostate cancer did not produce the expected cancer progression, consistent with saturation model. |
| Morgentaler A, Dhindsa S, Dobs AS, Hackett G, Jones TH, Kloner RA, Miner M, Zitzmann M, Traish AM 2024 · Mayo Clin Proc | observational | supports | moderate | Position paper notes TRAVERSE found no excess prostate-cancer events with TRT vs placebo, supporting non-causation at the population level. |
| Kaplan AL, Hu JC, Morgentaler A, Mulhall JP, Schulman CC, Montorsi F 2016 · Eur Urol | observational | supports | moderate | Reviews the paradigm shift showing no consistent increase in prostate cancer development or progression with testosterone therapy in men with cancer history. |
| Klotz L 2015 · Nat Rev Urol | observational | contradicts | moderate | Opinion review (one side of a Nat Rev Urol debate), no new data: 'the saturation model does not take the heterogeneity of human prostate cancer into account' and 'existing data are insufficient to exclude these adverse events.' An argument, not an observation - zero weight. |
| Welén K, Damber JE 2022 · Rev Endocr Metab Disord | observational | supports | moderate | Review concludes circulating androgen concentrations are not associated with risk of BPH development or PCa initiation/progression, attributing this to 'apparent insensitivity of prostatic tissue to changes of testosterone concent |
| Robinson J, Banerjee I, Banerjee I 2025 · Cureus | RCT | supports | low | Systematic review concludes exogenous TRT is not contraindicated post-definitive PCa treatment, does not alter intraprostatic DHEA, and castration-resistant PCa did not progress even under high-dose TRT (bipolar androgen therapy). |
| Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ 2012 · Eur Urol | observational | supports | high | In the REDUCE placebo arm, serum testosterone and DHT showed no association with prostate cancer risk, supporting a saturation effect at low androgen levels. |
| García-Becerra CA, Arias-Gallardo MI, Juárez-García JE, Soltero-Molinar V, Parra-Camaño LF, Rivera-Rocha MI, García-Becerra N, García-Gutiérrez CM 2026 · Int J Impot Res | meta-analysis | supports | moderate | Meta-analysis of 41 RCTs (n = 11,161): 'TTh was not associated with a statistically significant increase in ... PCaE (OR 0.88; 95% CI: 0.52-1.51; I² = 0.0%)'. This is the saturation model's PREDICTION holding, not the model itself being tested — the paper never mentions the saturation model, measures no androgen-receptor occupancy, no dose-response and no baseline-testosterone threshold; the mechanistic reading is ours. Supports at moderate quality: wide intervals over short- to mid-term trials, and the same pooled estimate also feeds the plain no-increased-prostate-cancer-risk appraisal. Paywalled; abstract-only. |
| Bhasin S, Thompson IM 2024 · J Clin Endocrinol Metab | RCT | supports | high | Synthesis of large RCTs (esp. TRAVERSE) shows testosterone therapy did not increase high-grade or any prostate cancer versus placebo in screened hypogonadal men. |
| Alexandre Alves VA, Brasileiro Silva AA, Falcao Bisneto EL, Macedo HF, Lima GS, Santos De Souza LGP, Barbosa PEA, Medeiros Júnior PF 2026 · Cureus | observational | supports | moderate | Systematic review finds TRT does not increase biochemical recurrence, progression, or mortality in low/intermediate-risk prostate cancer, consistent with the saturation model. |
| Xu Z, Chen X, Zhou H, Ren C, Wang Q, Pan Y, Liu L, Liu X 2024 · Front Endocrinol (Lausanne) | meta-analysis | supports | moderate | Meta-analysis of 28 RCTs (3,461 patients) found PSA was not significantly different between TRT and placebo groups (WMD 0.08; 95% CI -0.00-0.17; P=0.06), alongside no significant change in prostate volume. |
| Davidson E, Morgentaler A 2016 · Urol Clin North Am | observational | supports | moderate | Narrative review by the saturation model's originator (PubMed: Review): 'Evidence is reviewed herein regarding the relationship of testosterone to prostate cancer and the relatively new practice of offering testosterone therapy to men with a history of prostate cancer. Although no prospective controlled trials have been performed, results have been reassuring.' Review — zero weight. |
| Santucci J, Stapleton P, Perera M, Ischia J, Murphy D, Bolton D, Lawrentschuk N, Frydenberg M, Sathianathen N 2025 · BJU Int | observational | mixed | moderate | 2025 systematic review of TRT in localized prostate cancer: observational data broadly reassuring on oncologic safety, but evidence quality is low and no RCTs — cannot exclude harm. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.